Cargando…
Intrapleural interleukin-2–expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease
OBJECTIVE: The mainstay of treatment for patients with malignant pleural disease is fluid drainage and systemic therapy. A tumor-specific oncolytic virus or T-cell–activating interleukin-2 immunotherapy may provide an opportunity for local control. We previously developed a vaccinia virus–expressing...
Autores principales: | Ekeke, Chigozirim N., Russell, Kira L., Murthy, Pranav, Guo, Zong Sheng, Soloff, Adam C., Weber, Daniel, Pan, Wenjing, Lotze, Michael T., Dhupar, Rajeev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594625/ https://www.ncbi.nlm.nih.gov/pubmed/33485667 http://dx.doi.org/10.1016/j.jtcvs.2020.11.160 |
Ejemplares similares
-
Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
por: Ekeke, Chigozirim N., et al.
Publicado: (2021) -
Prognostic Difference of Pleural versus Distant Metastasis after Surgery for Lung Cancer
por: Joubert, Kyla D., et al.
Publicado: (2021) -
Delayed Chylothorax during Treatment of Follicular Lymphoma with a Malignant Pleural Effusion
por: Ekeke, Chigozirim N., et al.
Publicado: (2020) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012) -
HMGB1 Promotes Myeloid Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions
por: Soloff, Adam C., et al.
Publicado: (2020)